General (Details) $ / shares in Units, $ in Thousands																			1 Months Ended		3 Months Ended		12 Months Ended
	Jul. 11, 2020	Jun. 17, 2020 USD ($) $ / shares shares	Jun. 11, 2020 shares	Jun. 10, 2020	Jun. 01, 2020 USD ($)	May 22, 2020 item	Apr. 06, 2020 USD ($) $ / shares shares	Apr. 01, 2020 USD ($) shares	Mar. 27, 2020 USD ($) $ / shares shares	Mar. 25, 2020 $ / shares shares	Mar. 19, 2020 USD ($) $ / shares shares	Mar. 09, 2020 $ / shares	Mar. 06, 2020 USD ($) $ / shares	Mar. 05, 2020 USD ($) $ / shares	Jan. 14, 2020 shares	Jan. 09, 2020 USD ($) shares	Jun. 04, 2019 shares	Mar. 19, 2019 shares	Mar. 31, 2020 USD ($)	Jan. 31, 2020 shares	Jun. 30, 2020 USD ($)	Mar. 31, 2020 USD ($) shares	Dec. 31, 2019 USD ($)	May 01, 2020 USD ($)	Apr. 30, 2020 USD ($)	Jan. 08, 2020 USD ($)	Jul. 08, 2019 USD ($)
Lease concessions																			$ 75
Number of separate testing rooms						9															626
Number of tests per day | item						500
Long-lived assets and right-of-use assets																			22,891			$ 22,891
Reverse stock split, conversion ratio	0.33		0.33	0.33
Number of shares reduced | shares			3
Warrants to purchase shares of common stock | shares																	1,374,750	1,942,131
Number of shares converted from warrants | shares																	2,062,125					510,460
Working capital																									$ 27,800
Increase in principal and interest accrued of debt in new funding													$ 250
Conversion price | $ / shares													$ 1.68
Shares issued on conversion of debt | shares																		2,913,197
Shares issued | shares								201,666														6,511,280
Gross proceeds		$ 40,000						$ 43,050														$ 4,209
Cash and cash equivalents																			3,855			3,855	$ 2,184
Total current assets																			5,449			5,449	3,933
Total current liabilities																			16,103			16,103	16,220
Working capital deficiency																						10,654	12,287
Debt instrument, face amount													$ 7,900			$ 7,150			9,975			9,975				$ 7,000
Reduction in debt amount																			9,075			9,075
Additional amount borrowed																			4,880			4,880	5,762
Debt issuance costs																						400
Offerings
Warrants to purchase shares of common stock | shares		7,614,700
Warrant exercise price | $ / shares		$ 5.25
Warrants term		21 months
CC Agreement | CC Lender
Advance of funds																1,000
Aggregate fees																160
Total repayment																1,160						910
Discount on repayment of advances																						91
Credit agreement with B3D, LLC
Increase in principal and interest accrued of debt													750			$ 150
Increase in principal and interest accrued of debt in new funding													$ 500
Issuance of common shares to pay interest on borrowings | shares																97,223
Amount of principal to be converted into common stock									$ 375
Conversion price | $ / shares											$ 0.525	$ 1.68	$ 6.00	$ 6.00
Principal amount of debt converted											$ 750
Shares issued on conversion of debt | shares											446,429
Debt instrument, face amount														$ 7,150		$ 7,150										$ 7,000	$ 7,000
Write off of deferred debt issuance cost																						476
Purchase agreement
Warrants to purchase shares of common stock | shares							485,151		701,666	500,000	698,958
Shares issued | shares		7,614,700					4,049,573		2,631,666	2,483,333	1,396,281
Share price | $ / shares		$ 5.250					$ 0.66		$ 0.60	$ 0.60	$ 0.525
Offering price per First Pre-Funded Warrant | $ / shares							$ 0.63		$ 0.57	$ 0.57	$ 0.495
Gross proceeds							$ 3,050
Number of shares per warrant | shares							1
Warrant exercise price | $ / shares							$ 0.03
Payoff Letter | CC Lender
Total repayment					$ 733
Paycheck Protection Program
Debt instrument, face amount																								$ 5,653
B3D Note [Member]
Issuance of common shares to pay interest on borrowings | shares															97,223
Principal amount of debt converted																						5,665
Shares issued on conversion of debt | shares																				1,430,647
Additional amount borrowed																			3,562			3,562	4,580
Deferred finance costs																			189			189
Calm Note, net
Principal amount of debt converted																						2,500
Additional amount borrowed																			1,318			1,318	$ 1,182
Deferred finance costs																			$ 165			$ 165					$ 220
Warrants
Shares issued | shares																						1,900,625
Exercised | shares																						1,698,959
Gross proceeds																						$ 49